TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02743832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection for primary lesion and cervical lymph node dissection
Description: Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection for primary lesion and cervical lymph node dissection
Description: Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection for primary lesion only
Description: Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection for primary lesion only
Description: Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
Study: NCT04847661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
Description: Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
Description: Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
Study: NCT06349395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR surgical nursing care
Description: This study delivered an eight-session mindfulness-based stress reduction (MBSR) program online to its intervention group, each lasting about two hours, incorporating daily exercises monitored via phone. The evaluation of MBSR's effectiveness focused on postoperative pain at 6, 12, 18, and 24 hours after surgery and assessed fear of movement before starting arm exercises on the 5th day post-mastectomy. This approach provided a detailed examination of MBSR's role in pain and movement fear management, highlighting its potential as a preoperative care component for breast cancer patients.
Study: NCT06063421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette (EC)
Description: The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
Study: NCT04606459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary sinus reducer
Description: The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Guideline-directed medical therapy
Study: NCT05020600

Intervention type: DRUG
Intervention: Duloxetine
Description: First-line fibromyalgia treatment

Intervention type: DRUG
Intervention: Pregabalin
Description: First-line fibromyalgia treatment

Intervention type: DRUG
Intervention: Amitriptyline
Description: First-line fibromyalgia treatment
Study: NCT06311474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Description: PCIT is a dyadic therapy that focuses on enhancing the parent-child relationship and improving child behavior through positive parenting and limit setting skills. All PCIT sessions are delivered remotely via Zoom once per week for up to 20 weeks. Session length is about 1 hour. There are two distinct phases of PCIT, the Child Directed Interaction and the Parent Directed Interaction. Each phase begins with a Teach session, where parents learn about the skills they will practice during that portion of PCIT, and is followed by Coach sessions, in which the PCIT therapist provides direct feedback and live coaching on the use of the skills. An additional component is Daily Play practice. Parents are instructed to spend five minutes per day playing with their child, during which they practice skills learned during sessions. Adaptations have been made to the standard approach to increase suitability for the TSC population.
Study: NCT04870476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered treatment: One step at the time
Description: The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks. The content is written psychoeducation, patient videos, audio exercises and exposure exercises. The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
Study: NCT05598892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with Robotic Hand Exoskeleton
Description: The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
Study: NCT04856553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effects of handgrip exercise
Description: The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effects of handgrip exercise
Description: The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
Study: NCT05687084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine manipulator use
Description: The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
Study: NCT05700903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin Releasing Hormone Agonists (GNRH)
Description: 8 weeks of GnRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin Releasing Hormone Agonists (GNRH)
Description: 8 weeks of GnRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen receptor (AR) inhibitor
Description: 2 weeks of AR Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen receptor (AR) inhibitor
Description: 2 weeks of AR Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and injection
Study: NCT05704478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vericiguat
Description: soluble guanylate cyclase stimulator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vericiguat
Description: soluble guanylate cyclase stimulator
Study: NCT05430100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns
Description: 5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns
Description: The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns
Description: The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
Study: NCT04788043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: 45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Scan
Study: NCT05044156

Intervention type: OTHER
Intervention: salivary sample
Description: salivary sample

Intervention type: OTHER
Intervention: salivary sample
Description: salivary sample
Study: NCT04854681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 Injection
Description: 4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
Study: NCT05318456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MoodElite T-4003-1
Description: Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
Study: NCT06022263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: 180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
Study: NCT05495893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
Study: NCT05419089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
Study: NCT06207136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Description: Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean-style diet
Description: Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
Study: NCT06454331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The two key landmarks for EEG electrode placement are the nasion and the inion which are used to define the measurement. Measure the distance between the nasion and the inion along the midline of the head. Divide the nasion-inion distance by two to find the midpoint and mark this midpoint on the scalp along the midline. C3 (left hemisphere of the scalp) and C4 (right hemisphere of the scalp), which are placed 20% of the nasion-inion distance from the midline, and M1, which is placed 10% of this distance from the midline, can be determined using these calculations. From the midpoint marked on the scalp, measure to the left and right sides using the calculated 10% and 20% distances. Mark these points as M1 and its mirror position. Clean the scalp at the marked M1 and its mirror position locations to remove any oils or debris.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The two key landmarks for EEG electrode placement are the nasion and the inion which are used to define the measurement. Measure the distance between the nasion and the inion along the midline of the head. Divide the nasion-inion distance by two to find the midpoint and mark this midpoint on the scalp along the midline. C3 (left hemisphere of the scalp) and C4 (right hemisphere of the scalp), which are placed 20% of the nasion-inion distance from the midline, and M1, which is placed 10% of this distance from the midline, can be determined using these calculations. From the midpoint marked on the scalp, measure to the left and right sides using the calculated 10% and 20% distances. Mark these points as M1 and its mirror position. Clean the scalp at the marked M1 and its mirror position locations to remove any oils or debris.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation
Description: it can apply in sitting or supine lying position but it's important to ensure their comfort and safety while facilitating optimal electrode placement and contact with the scalp. Duration of 20 minutes, with Intensity of 0.5mA, and density of 0.02 mA/cm² for 8 weeks on alternative days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: it can apply in sitting or supine lying position but it's important to ensure their comfort and safety while facilitating optimal electrode placement and contact with the scalp. Duration of 20 minutes, with Intensity of 0.5mA, and density of 0.02 mA/cm² for 8 weeks on alternative days
Study: NCT05201833

Intervention type: BEHAVIORAL
Intervention: Telephone Outcome Assessment
Description: Assessments will be administered over the telephone to evaluate participant outcome status

Intervention type: BEHAVIORAL
Intervention: Telephone Outcome Assessment
Description: Assessments will be administered over the telephone to evaluate participant outcome status

Intervention type: BEHAVIORAL
Intervention: Telephone Outcome Assessment
Description: Assessments will be administered over the telephone to evaluate participant outcome status

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: Assessments will be administered to evaluate participant outcome status

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: Assessments will be administered to evaluate participant outcome status

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: Participants will be asked to complete a 3T MRI

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: Participants will be asked to complete a 3T MRI

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood Draw for Plasma, DNA, Serum, RNA

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood Draw for Plasma, DNA, Serum, RNA
Study: NCT04638569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: obturator nerve block
Description: The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: obturator nerve block
Description: The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
Study: NCT04438174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Processed Amniotic Fluid
Description: Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Wound Treatment Regimen
Description: ointment-based dressing and non-ointment-based dressings
Study: NCT04840680

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05298137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Leg Raise
Description: A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
Study: NCT05034965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid filler injection
Description: quantitative surface electromyography before injection(baseline) and one week after injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid filler injection
Description: quantitative surface electromyography before injection(baseline) and one week after injection
Study: NCT05246137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine 40 ug/dose
Description: Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
Study: NCT05331885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suvratoxumab
Description: Monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only excipients
Study: NCT05603715

Intervention type: DRUG
Group type: OTHER
Intervention: Pyridostigmine Bromide
Description: Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
Study: NCT05047757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal with 15N labeled favabean
Description: Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
Study: NCT05024955

Intervention type: PROCEDURE
Intervention: Discussion
Description: Attend a focus group

Intervention type: OTHER
Intervention: Interview
Description: Attend interview
Study: NCT05360056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DexCom G6
Description: Wearable continuous glucose monitor